{
    "eid": "2-s2.0-85115864533",
    "title": "Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "cccDNA transcription",
        "farnesoid X receptor",
        "HBV therapy",
        "phase Ib",
        "Vonafexor"
    ],
    "authors": [
        "Robin Erken",
        "Patrice Andre",
        "Elise Roy",
        "Neeltje Kootstra",
        "Noelie Barzic",
        "Hugo Girma",
        "Christian Laveille",
        "Pauline Radreau-Pierini",
        "Raphael Darteil",
        "Jacky Vonderscher",
        "Pietro Scalfaro",
        "Pisit Tangkijvanich",
        "Robert Flisiak",
        "Henk Reesink"
    ],
    "citedby-count": 12,
    "ref-count": 34,
    "ref-list": [
        "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study",
        "European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection",
        "The role of cccDNA in HBV maintenance",
        "What is new on HBsAg and other diagnostic markers in HBV infection?",
        "Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine",
        "Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis",
        "Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism",
        "Limited effects of fasting on hepatitis B virus (HBV) biosynthesis in HBV transgenic mice",
        "The metabolic sensors FXRalpha, PGC-1alpha, and SIRT1 cooperatively regulate hepatitis B virus transcription",
        "Farnesoid X receptor-\u03b1 is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo",
        "Reciprocal regulation of farnesoid X receptor alpha activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes",
        "Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha",
        "Limited effects of bile acids and small heterodimer partner on hepatitis B virus biosynthesis in vivo",
        "Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis",
        "Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide",
        "Role of bile acids and bile acid receptors in metabolic regulation",
        "Independent activation of hepatitis B virus biosynthesis by retinoids, peroxisome proliferators, and bile acids",
        "Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo",
        "Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death",
        "Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor",
        "Hepatitis B virus protein X induces degradation of Talin-1",
        "In vitro characterization of Eyp001 a novel, potent and selective FXR agonist entering phase 2 clinical trials in chronic hepatitis B",
        "Clinical syndromes and consequences of antiretroviral-related hepatotoxicity",
        "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial",
        "A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis",
        "Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial",
        "Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management",
        "Liver safety assessment in clinical trials of new agents for chronic hepatitis B",
        "Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad",
        "Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury",
        "RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg",
        "Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial",
        "Hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B patients during peginterferon treatment"
    ],
    "affiliation": [
        {
            "affiliation-city": "Amsterdam",
            "@id": "60002483",
            "affilname": "Universiteit van Amsterdam",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002483",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Bialystok",
            "@id": "60087887",
            "affilname": "Uniwersytecki Szpital Kliniczny w Bia\u0142ymstoku",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60087887",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Villeurbanne",
            "@id": "60023578",
            "affilname": "Universit\u00e9 Claude Bernard Lyon 1",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023578",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Leiden",
            "@id": "60015618",
            "affilname": "Leids Universitair Medisch Centrum",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015618",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Liergues",
            "@id": "119686256",
            "affilname": "Calvagone",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/119686256",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Lyon",
            "@id": "115168231",
            "affilname": "ENYO-Pharma",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115168231",
            "affiliation-country": "France"
        }
    ],
    "funding": [
        "Data Safety Monitoring Committee",
        "Enyo Pharma",
        "French Agence Nationale de la Recherche sur le sida et les H\u00e9patites Virales"
    ]
}